Working… Menu

Special Drug Use Surveillance of Irribow in Female Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02612649
Recruitment Status : Completed
First Posted : November 24, 2015
Last Update Posted : October 17, 2018
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.

Condition or disease Intervention/treatment
Diarrhea-predominant Irritable Bowel Syndrome Drug: Ramosetron

Layout table for study information
Study Type : Observational
Actual Enrollment : 793 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients
Actual Study Start Date : October 1, 2015
Actual Primary Completion Date : March 31, 2018
Actual Study Completion Date : March 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea

Group/Cohort Intervention/treatment
Ramosetron group
Female patients with diarrhea-predominant irritable bowel syndrome
Drug: Ramosetron
Other Names:
  • YM060
  • Irribow

Primary Outcome Measures :
  1. Incidences of Adverse Drug Reactions [ Time Frame: Up to Week 52 ]

Secondary Outcome Measures :
  1. Change from baseline in frequency of bowel movements [ Time Frame: Baseline to Week 52 ]
    Frequency of bowel movements is recorded daily

  2. Change from baseline in form of stool [ Time Frame: Baseline to Week 52 ]
    Classified based on Bristol Stool Form Scale

  3. Change from baseline in sensation of incomplete bowel evacuation [ Time Frame: Baseline to Week 52 ]
    Assessment based on numerical rating scale

  4. Change from baseline in defecation urgency [ Time Frame: Baseline to Week 52 ]
  5. Change from baseline in abdominal pain or discomfort [ Time Frame: Baseline to Week 52 ]
    Abdominal pain or discomfort assessed based on numerical rating scale

  6. Change from baseline in melena [ Time Frame: Baseline to Week 52 ]
  7. Overall improvement [ Time Frame: Up to Week 52 ]
    Classified into the three scales (improved, no change or aggravated) or concluded as indeterminable.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Female patients with diarrhea-predominant irritable bowel syndrome

Inclusion Criteria:

  • Female patients with diarrhea-predominant irritable bowel syndrome

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02612649

Layout table for location information
Aichi, Japan
Akita, Japan
Chiba, Japan
Fukui, Japan
Fukuoka, Japan
Fukushima, Japan
Gifu, Japan
Gunma, Japan
Hiroshima, Japan
Hyogo, Japan
Ibaraki, Japan
Iwate, Japan
Kagoshima, Japan
Kanagawa, Japan
Kumamoto, Japan
Kyoto, Japan
Mie, Japan
Miyagi, Japan
Miyazaki, Japan
Nagano, Japan
Niigata, Japan
Oita, Japan
Okayama, Japan
Okinawa, Japan
Osaka, Japan
Saitama, Japan
Shiga, Japan
Shizuoka, Japan
Tochigi, Japan
Tokyo, Japan
Tottori, Japan
Toyama, Japan
Yamagata, Japan
Yamaguchi, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Layout table for investigator information
Study Director: Medical Director Astellas Pharma Inc

Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT02612649     History of Changes
Other Study ID Numbers: IB0002
First Posted: November 24, 2015    Key Record Dates
Last Update Posted: October 17, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on under "Sponsor Specific Details for Astellas."
Keywords provided by Astellas Pharma Inc:
Irritable bowel syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action